Targeted induction before immunotherapy shows limited benefit in advanced melanoma

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
However, findings presented at ASCO Annual Meeting suggest that individuals with elevated lactate dehydrogenase or liver metastases may benefit from the treatment regimen.
“These are, most of the time, the patients for whom we are giving a targeted therapy first line,” Caroline Robert, MD, PhD, head of dermatology at Gustave Roussy Cancer Campus and co-director of the

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
However, findings presented at ASCO Annual Meeting suggest that individuals with elevated lactate dehydrogenase or liver metastases may benefit from the treatment regimen.
“These are, most of the time, the patients for whom we are giving a targeted therapy first line,” Caroline Robert, MD, PhD, head of dermatology at Gustave Roussy Cancer Campus and co-director of the